$PTP (-4,43 %) Pentixapharm,

What exactly is the company that was spun off from Eckert and Ziegler? $EUZ (+1,36 %) was spun off?

Andreas Eckert - founder of Eckert on this:

4 active ingredients including 2 in phase III and 2 in I/IIa

Target 2027 to bring both phase III diagnostics to market with EUR 55m expenditure.

However, further financing measures are required here.

20.8 million shares + 3.9 million in free float.

Other competitors in the market are

Telix Pharma and $TLX (-2,61 %)

Lantheus Holding $LNTH (-0,47 %)